Zbigniew Deron

Lodz, LD 91347, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study.

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study.

Journal: Journal of clinical medicine

Published: July 23, 2022

HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study.

HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study.

Journal: Journal of clinical medicine

Published: December 09, 2021

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.

Journal: World journal of gastroenterology

Published: January 26, 2021

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?

Journal: Journal of gastroenterology and hepatology

Published: September 10, 2020

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA.

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA.

Journal: Expert review of anti-infective therapy

Published: June 16, 2020

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection.

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection.

Journal: Polish archives of internal medicine

Published: February 08, 2020

Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients - short report.

Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients - short report.

Journal: Clinical and experimental hepatology

Published: January 03, 2020

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.

Journal: Journal of gastroenterology and hepatology

Published: September 05, 2019

Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 study.

Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 study.

Journal: AIDS care

Published: July 27, 2019

Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis.

Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis.

Journal: Advances in medical sciences

Published: February 09, 2019

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting.

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting.

Journal: Archives of medical science : AMS

Published: January 23, 2019

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.

Journal: BMC infectious diseases

Published: May 22, 2018

Showing 1-12 of 21

Last Updated: 09/26/2026